Company profile
Evofem Biosciences, Inc. CIK 1618835
Ticker
EVFM (OTC)
Industry
Pharmaceutical Preparations
Headquarters
San Diego, CA 92130
Fiscal year end
2025 (FY)
Key Financials
Revenue
$20.18M
Net income
$391.0K
Total assets
$20.27M
Total liabilities
$89.71M
Stockholders' equity
-$74.34M
Cash & equivalents
$578.0K
Operating income
$3.37M
Operating cash flow
-$1.99M
Capital expenditures
$5.0K
Fiscal year 2025, via 10-K filed 2026-03-11. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
16.7%
Net margin
1.9%
Free cash flow
-$2.00M
Free cash flow margin
-9.9%
Liabilities / assets
442.5%
Equity / assets
-366.7%
CapEx / revenue
0.0%
Operating cash flow / net income
-5.09×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$20.18M
$391.0K
$20.27M
$89.71M
-$74.34M
2024
$19.36M
-$8.86M
$23.79M
$90.26M
-$71.26M
2023
$18.22M
$52.98M
$10.55M
$72.47M
-$66.51M
2022
$16.84M
-$76.70M
$25.16M
$96.96M
-$71.80M
2021
$8.24M
-$205.19M
$42.51M
$142.09M
-$104.32M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-14
Financials filed via
Form 10-K
filed 2026-03-11
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
San Diego, CA 92130
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:18 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.